Edited by the Editors  · 

The third issue of The Bioneer is a careful one. Hormones are, in the wellness category, the most over-sold, most under-investigated, most thoughtfully practiced, and most recklessly practiced therapeutic class at the same time. The issue argues that the difference between care and commerce here is usually the length of the conversation and the breadth of the panel, not the prescription. It is a long issue. It is meant to be read slowly.

This page is a preview. The print edition arrives with members the first Monday in June. The digital edition is emailed from hello@mywellnesscorporation.com and mirrored here at publication. Subscribers who join before June 1 will receive the issue on launch day.

In this issue

Feature  ·  18 min
Where the Line Is. — Dr. Chaudhari on the distinction between thoughtful hormone care and the men’s-clinic model that has dominated the category for a decade. What gets measured before a single milliliter is prescribed. What a “no” looks like and when he says it.
Protocol  ·  12 min
The Full Panel. — What a complete hormone panel actually includes, why the eight-marker supermarket version is insufficient for any serious decision, and what members should expect to see on their printout — free T, total T, SHBG, estradiol, DHT, prolactin, FSH, LH, and the supporting-cast markers the good clinic orders anyway.
The Insight  ·  10 min
Women in Midlife and the Conversation the System Is Not Having. — Perimenopausal and menopausal care, the retreat from hormone therapy after the WHI study and the slow, evidence-based return, and what the 2023 Menopause Society position statement actually changed. Written for the woman whose primary care visit was twelve minutes long and left her with no plan.
The Question  ·  9 min
On Peptides. — The category is moving faster than the evidence. A careful read of BPC-157, thymosin-alpha, CJC/ipamorelin, and tesamorelin — what the data supports, what remains animal-model optimism, and what the clinic currently prescribes and does not.
Interview  ·  26 min
An Endocrinologist on the Difference Between Treatment and Optimization. — A visiting specialist on hypogonadism, subclinical thyroid, and where the scope of “normal range” is misleading a generation of motivated patients into either over-treatment or under-treatment, depending on which side of the table they sit on.
Member Portrait  ·  14 min
The Member Who Declined TRT. — A sixty-one-year-old man whose total testosterone was borderline low, whose symptoms were modest, and who was offered testosterone replacement at three other clinics. He declined at WEF after the physician walked him through what the data actually said for someone in his specific clinical picture. His numbers now, eighteen months later, without treatment.
The Long Arc  ·  12 min
Hormones and the Decade Ahead. — What the best evidence suggests about hormone trajectories from forty to eighty, what is worth treating, what is worth monitoring, and what is worth leaving alone. A physician’s argument against the over-medicalization of aging and, simultaneously, for the under-treatment of real clinical need.
We do not optimize a number out of physiologic range because the member wants to. That is not medicine. Dr. Swet Chaudhari, MD  ·  from the issue

A preview, from “Where the Line Is”

The test for whether a clinic is practicing medicine or practicing commerce is the conversation before the first prescription. A clinic practicing medicine orders a full panel, reads the full panel, asks about the history, asks about the symptoms, and almost always orders a second panel before it will move. A clinic practicing commerce has a protocol that starts with testosterone cypionate on the first visit, and the conversation is twenty-five minutes long, and the answer is the same answer the previous patient got. The member cannot always tell which clinic they are in by the décor. They can almost always tell by how long the intake took.

Our practice is the slower one. We lose revenue on the members we decline. We have lost members to other clinics who told them what they wanted to hear. Some of those members have come back eighteen months later with labs we had to spend a year correcting. I am not writing that last sentence as marketing. I am writing it as a warning. Hormones are useful. Hormones are also networked, and the networks are not forgiving of the short-form version of the conversation.

The full piece, plus six more, publishes 2 June 2026. Subscribe below to receive the issue at launch.

— Published in The Bioneer, Magazine.